Effect of Desmopressin on Platelet Function in CKD Patients on Antiplatelet Drug

• Status: Completed
• Trial end date: 2013-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Prolonged Collagen/Epinephrine - closure time (CEPI-CT) indicates platelet dysfunction in CKD patients taking antiplatelet agent. The synthetic vasopressin derivative, Desmopressin (DDAVP) shortens the prolonged bleeding time and improves platelet dysfunction measured by in vitro closure time: CEPI-CT in uremic patients. Desmopressin also antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors, clopidogrel and aspirin. The investigators designed a prospective study to evaluate the effect of desmopressin on platelet function, as measured by in vitro collagen/epinephrine - closure time, in uremic patients who were taking antiplatelet drugs.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Ulsan
• Treatments: Deamino Arginine Vasopressin; Platelet Aggregation Inhibitors

Criteria

Inclusion Criteria:

• adult uremic patients with one or more antiplatelet medication,

• prolonged collagen/epinephrine (CEPI) closure time,

• need for emergent hemodialysis and

• subsequent catheter insertion

Exclusion Criteria:

• acute coronary syndrome,

• hemophilia, and nephrogenic diabetes insipidus,

• allergy against desmopressin